Meeting
2012 ASCO Annual Meeting
A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy (NACT) for early breast cancer: Three-year follow-up data.
Authors
Andreas Schneeweiss
University Hospital Heidelberg, Heidelberg, Germany
Andreas Schneeweiss , Amparo Ruiz , Alexey Manikhas , Alberto Bottini , Pedro Sanchez Rovira , Kambiz Mansouri , Gbenga Kazeem , Thomas Bauknecht
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Clinical Trial Registration Number
NCT00149214
Citation
J Clin Oncol 30, 2012 (suppl; abstr 1059)
DOI
10.1200/jco.2012.30.15_suppl.1059
Abstract #
1059
Poster Bd #
22B
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A randomized phase II trial comparing docetaxel plus cyclophosphamide with epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for hormone receptor-negative breast cancer: Kanagawa Breast Oncology Croup (KBOG) 1101 study.
First Author: Takashi Ishikawa
Poster
2013 ASCO Annual Meeting
Sixteen years follow-up results of a randomized phase II trial of neoadjuvant FAC compared with CMF in stage III breast cancer.
First Author: Ariel Osvaldo Zwenger
Poster
2011 ASCO Annual Meeting
Multigene predictors developed on breast cancer cell lines to predict patient chemotherapy response: A validation study on the NSABP B-27 trial.
First Author: K. Shen
Poster
2023 ASCO Annual Meeting
Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers.
First Author: Sara P. Myers